You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 26, 2024

Claims for Patent: 5,372,808

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 5,372,808

Title:	Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
Abstract:	Methods for the treatment of cell proliferation disorders, viral infections, and other conditions without causing significant side effects normally associated with interferon therapy, involving administering to a patient in need thereof a therapeutically effective amount of consensus human leukocyte interferon are disclosed. Also disclosed are pharmaceutical compositions of consensus human leukocyte interferon.
Inventor(s):	Blatt; Lawrence M. (Ventura, CA), Taylor; Milton W. (Bloomington, IN)
Assignee:	Amgen Inc. (Thousand Oaks, CA)
Application Number:	07/868,916
Patent Claims:	1. A method for treating a patient having a viral disease selected from the group consisting of hepatitis A, hepatitis B, hepatitis C or hepatitis Delta while reducing the occurrence of Grade 3or 4 toxicities associated with alpha interferon treatment as measured by the World Health Organization toxicity scale, which comprises administering to said patient a therapeutically effective amount of a consensus human leukocyte interferon. 2. A method according to claim 1, wherein said viral disease is hepatitis A. 3. A method according to claim 1, wherein said viral disease is hepatitis B. 4. A method according to claim 1, wherein said viral disease is hepatitis C. 5. A method according to claim 1, wherein said viral disease is hepatitis Delta. 6. A method for treating a patient having Kaposi's Sarcoma while reducing the occurrence of Grade 3 or 4 toxicities associated with alpha interferon treatment as measured by the World Health Organization toxicity scale, which comprises administering to said patient a therapeutically effective amount of a consensus human leukocyte interferon. 7. A method according to claim 1 or 6, wherein said toxicities are selected from the group consisting of headache, fever, chills, nausea, anorexia. depression, and insomnia. 8. A method according to claim 1 or 6, wherein the consensus human leukocyte interferon is :;elected from the group consisting of IFN-con.sub.1, IFN-con.sub.2, and IFN-con.sub.3. 9. A method according to claim 1 or 6, wherein the consensus human leukocyte interretort is ZFN-con.sub.1. 10. A method according to claim 1 or 6, wherein the consensus human leukocyte interferon is a product of procaryotic expression of an exogenous DNA sequence. 11. A method according to claim 1 or 6, wherein the therapeutically effective amount is administered by a route of administration selected from the group consisting of oral, intravenous, intramuscular. subcutaneous, intranasal, and intralesional. 12. A method according; to claim 1 or 6, wherein the therapeutically effective amount of consensus human leukocyte interferon is from 2.times.10.sup.6 to 30.times.10.sup.6 units per patient. 13. A method according to claim 1 or 6, wherein the therapeutically effective amount of consensus human leukocyte interferon is from 6.times.10.sup.6 to 15.times.10.sup.6 units per patient. 14. A method according to claim 1 or 6, wherein the patient is a human. 15. A method according to claim 1 or 6, further comprising administering a therapeutically effective amount of a chemotherapeutic agent. 16. A method according to claim 1 or 6, further comprising administering: a therapeutically effective amount of G-CSF.

Details for Patent 5,372,808

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Kadmon Pharmaceuticals Llc	INFERGEN	interferon alfacon-1	Injection	103663	October 06, 1997	⤷ Subscribe	2011-12-13
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 5,372,808

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration
South Africa	932641	⤷ Subscribe
World Intellectual Property Organization (WIPO)	9321229	⤷ Subscribe
World Intellectual Property Organization (WIPO)	9206707	⤷ Subscribe
Ukraine	44223	⤷ Subscribe
Taiwan	265265	⤷ Subscribe
Slovakia	284712	⤷ Subscribe
Slovakia	124794	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.